Cure My Disease

Don't miss your cure!

 Log in / Sign up

Treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the chinese population

NCT ID NCT07809178

NEW Sponsor: Cheng sen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 09, 2026

Summary

The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population. The main question it aims to answer is: For patients with tumor in sellar region combined with unruptured intracranial aneurysms, which condition should be treated first?

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 608 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed of tumor in sellar region with unruptured intracranial aneurysms in the Chinese population

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Preoperative enhanced head MRI showing a suspected diagnosis of a sella region lesion, and preoperative head CTA/DSA confirming an unruptured intracranial aneurysm. 2. Patients with primary sella region tumor and unruptured intracranial aneurysms that have not previously accepted surgical treatment. 3. Patients with tumor in sellar region requiring craniotomy or endoscopic transnasal surgery and/or an aneurysm requiring craniotomy, endovascular treatment, or observation only. 4. The patients are in good general health, without severe underlying medical conditions, and capable of tolerating surgical treatment. 5. Patients or their legal guardians have signed an informed consent form and voluntarily agreed to participate in the clinical trial. Exclusion Criteria: 1. Patients with recurrent sella region tumors. 2. Patients with previously treated intracranial aneurysm. 3. Pregnant or breastfeeding women. 4. Any other condition that, in the investigator's judgment, makes the patient unsuitable for trial participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chordoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system cyst chordoma craniopharyngioma germinoma hypothalamic neoplasm meningioma optic pathway glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chordoma Craniopharyngioma Germinoma Hypothalamic neoplasms Meningioma Optic pathway glioma Pituitary neuroendocrine tumor Rathke cleft cysts Unruptured intracranial aneurysms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Tiantan Hospital affiliated to Capital Medical University

    Beijing, China, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.